Osteomyelitis is a severe infection of bone tissue that results in progressive inflammatory destruction of bone (41) . The gram-positive organism Staphylococcus aureus is the most common causative agent of osteomyelitis, accounting for approximately 80% of all human cases (27) . It is often necessary that infected bone be debrided, tissues reconstructed, and longterm antibiotic therapy utilized (18) . The current treatment for osteomyelitis is often traumatic and expensive and often leads to further selection of antibiotic-resistant strains of S. aureus. The growing incidence of antibiotic-resistant S. aureus strains can explain the recurrent attacks of osteomyelitis in patients undergoing therapy. In addition, the pathogenesis of S. aureusinduced osteomyelitis is poorly understood. Elucidating the mechanisms by which S. aureus induces osteomyelitis could therefore lead to a better understanding of the disease, its progression, and development of new treatments.
Bone remodeling involves a continuous, coordinated equilibrium between bone synthesis and bone resorption, and two cell populations are responsible for the continual process (23) . Osteoclasts drive the resorption of bone by acidification and release of lysosomal enzymes, while osteoblasts produce components of the bone matrix, principally type I collagen. Osteoblasts also produce factors which serve to modulate the activity or formation of osteoclasts (1) . One such key molecule produced by osteoblasts is receptor activator of NF-B ligand (RANK-L), which on binding to RANK, found on osteoclast precursors, triggers intricate and distinct signaling cascades that control lineage commitment and activation of osteoclasts (53) . RANK-L is therefore thought to be the essential and final common signal required both in vitro and in vivo for full osteoclastic differentiation from multipotential hematopoietic precursor cells into mature multinucleated bone-resorptive osteoclasts (22, 24, 25) . Thus, osteoblasts can regulate both net bone formation and resorption.
Prostaglandin E 2 (PGE 2 ) is produced in bone mainly by osteoblasts and acts as a potent stimulator of bone resorption by inducing osteoclast formation in both mouse bone marrow cultures and calvarial cultures (1, 7, 37, 40, 46, 48) . PGE 2 synthesis is regulated by three metabolic steps: the release of arachidonic acid from the membranous phospholipids by phospholipase A 2 , the conversion of arachidonic acid to prostaglandin H 2 (PGH 2 ) by cyclooxygenase (COX), and the synthesis of PGE 2 catalyzed by PGE synthase (9, 20, 26, 34, 42, 44, 50) . Although both constitutive COX (COX-1) and inducible COX (COX-2) are expressed in mouse osteoblasts, the expression of COX-2 is markedly induced by several proinflammatory cytokines, such as interleukin 6 (IL-6). Bost et al. (5, 11) have reported that S. aureus-infected osteoblasts produce high levels of IL-6, which have been shown to modulate the activity of bone-resorptive osteoclasts either directly or indirectly (21, 45) . It has also been determined that PGE 2 can upregulate RANK-L expression in osteoblasts (16, 17, 54, 57) .
Bacterial pathogens can stimulate osteoclastogenesis, which can potentiate bone resorption, leading to bone destruction (31). Okahashi et al. have also demonstrated that normal mouse osteoblasts infected with Streptococcus pyogenes increase expression of RANK-L mRNA and protein (36) . In addition, elevated levels of RANK-L have been detected in the bone lesions of mandibular osteomyelitis (33) . We therefore propose that following an intracellular challenge with S. aureus, osteoblasts can increase RANK-L expression, which could stimulate osteoclast activity and thereby potentiate the massive bone loss that occurs in S. aureus-infected bone tissue. The current study investigates RANK-L mRNA and protein expression during normal mouse osteoblast infection with S. aureus. Such a proposed upregulation of RANK-L from infected osteoblasts could be mediated either directly or indirectly. Since it has been determined that PGE 2 can upregulate RANK-L, we propose in the current study that PGE 2 production by S. aureus-infected osteoblasts will be increased and that inhibition of PGE 2 by the specific COX-2 inhibitor NS-398 will result in decreased levels of PGE 2 and RANK-L by infected osteoblasts.
MATERIALS AND METHODS
Bacterial strains. Staphylococcus aureus strain UAMS-1 (ATCC 49230) is a human osteomyelitis clinical isolate (15) . Staphylococcus carnosus (ATCC 51365) is a nonpathogenic species with a reduced ability to invade osteoblasts (11) . Strains N1, N2, N3, N4, and N5 are Staphylococcus aureus nasopharyngeal isolates kindly provided by Vance G. Fowler, Jr. (Duke University Medical Center).
Isolation and culture of mouse osteoblasts. Osteoblasts were isolated from the calvariae of 2-day-old CD-1 mice by sequential collagenase and protease digestions as described previously (38) .
Invasion assay. The invasion assay with live or UV-killed S. aureus strain UAMS-1, live S. carnosus, or live nasopharyngeal isolates was carried out as previously described (11, 12) . Briefly, bacteria were grown overnight (16 h) in 5 ml of tryptic soy broth in a shaking water bath at 37°C. The bacteria were harvested by centrifugation for 10 min at 4,300 ϫ g at 4°C and washed twice. The pellets were then resuspended in 5 ml of growth medium lacking antibiotics/ antimycotics. Confluent cell layers of osteoblasts were washed three times to remove the growth medium. The cultures were then infected at a multiplicity of infection (MOI) of 25:1 or 75:1 with S. aureus strain UAMS-1 or with S. carnosus, UV-killed S. aureus, or the nasopharyngeal isolates at a MOI of 25:1 in 4 ml of growth medium lacking antibiotics/antimycotics. Following a 45-min infection period, infected cell cultures were washed three times and incubated for 1 h in growth medium containing 25 g of gentamicin/ml to kill the remaining extracellular bacterial cells. The osteoblast cultures were washed and subsequently lysed at different time points by the addition of 1.2 ml of 0.1% Triton X-100 (Fisher Biotech, Fair Lawn, NJ) with incubation for 5 min at 37°C.
Quantitative real-time PCR. To quantify RANK-L mRNA, real-time PCR was performed using a Roche LightCycler 2.0 instrument with the Sybr green reagent (Qiagen, Valencia, CA) according to the manufacturer's instructions. Amplicons of RANK-L and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) were used to develop a standard curve. Samples were subjected to 40 cycles of amplification consisting of 95°C for 15 s followed by 53°C for 20 s. Each assay was normalized to G3PDH mRNA. PCR primers were derived from published sequences (IDT, Coralville, IA) (36) . Positive-and negative-strand primers were as follows: RANK-L (89 bp), 5Ј-TACTTTCGAGCGCAGATGGAT-3Ј and 5Ј-AC CTGCGTTTTCATGGAGTCT-3Ј; G3PDH (63 bp), 5Ј-AACTACATGGTCTA CATGTTCCA-3Ј and 5Ј-CCATTCTCGGCCTTGACTGT-3Ј.
Protein isolation. Osteoblasts were isolated and seeded at 10 6 cells per well in six-well plates and infected once the cells had reached confluence (6 to 8 days). Following a 45-min incubation with or without bacteria and a 1-h treatment with 25 g/ml gentamicin sulfate, total protein was isolated from the osteoblasts at 0, 6, and 24 h using a tissue protein extraction reagent (Pierce, Rockford, IL) with additional protease inhibitors, aprotinin (2 g/ml) and leupeptin (2.5 g/ml) (Sigma Chemical Company, St. Louis, MO). Two hundred l of the tissue protein extraction reagent was added to each well at the appropriate time point, and cells were removed from the culture plates with a cell scraper (Costar). Samples were collected in 1.5-ml microcentrifuge tubes and then centrifuged at 10,000 ϫ g for 2 min to pellet cell debris. Supernatants were collected, and placed in fresh tubes, and stored at Ϫ80°C.
Inhibitor study. Osteoblasts were isolated and cultured in six-well plates as described previously. Forty-eight hours prior to infection, cells were treated with either 0.025% dimethyl sulfoxide (DMSO) or 20 M NS-398 (Cayman Chemicals, Ann Arbor, MI), a specific COX-2 inhibitor, dissolved in DMSO at an optimal dose that was previously determined to provide inhibition of COX-2 (6, 58). Following the 48-h treatment, cells were rinsed one time with osteoblast growth medium (OBGM) containing no gentamicin sulfate or amphotericin B. One ml of OBGM, containing no gentamicin sulfate or amphotericin B and containing either DMSO or NS-398, was then added to each appropriate well. The osteoblasts were either uninfected (MOI ϭ 0) or infected with the bacterial strains noted above using the method described previously. Following the 45-min incubation with or without bacteria, each well was rinsed one time with OBGM. One ml of fresh medium, containing either DMSO or NS-398 and 25 g/ml of gentamicin, was then added to each well. Cells were then incubated for 1 h at 37°C in a 5%-CO 2 atmosphere to allow the remaining extracellular bacteria to be killed. Following the 1-h incubation period, protein samples were isolated as described previously (time zero). Samples were also isolated at 6 h and 24 h following time zero. In addition, culture supernatants were collected and stored at Ϫ80°C.
Quantification of RANK-L protein and PGE 2 . Using protein samples collected as described previously, a mouse TRANCE/TNSF11/RANK ligand enzymelinked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) was used to detect the levels of RANK-L in osteoblast whole-cell extracts. A PGE 2 correlate enzyme immunoassay (EIA) (Assay Designs, Ann Arbor, MI) was performed with the cell culture supernatants following the manufacturer's instructions.
Statistical analysis. Data were analyzed using a two-way analysis of variance followed by the Tukey-Kramer multiple-comparison analysis. Results are presented as the means Ϯ standard errors. For all tests, P values of Ͻ0.05 were considered significant.
RESULTS
Induction of RANK-L mRNA expression in osteoblasts following exposure to bacteria. Staphylococcal osteomyelitis is associated with increased osteoclast activity, and RANK-L is a key factor required for osteoclastogenesis (24, 25, 46, 57) . Therefore, it is important to determine whether osteoblasts infected with S. aureus produce RANK-L and if the levels of RANK-L increase in a time-and dose-dependent manner. Quantitative analysis by real-time reverse transcription-PCR demonstrated that RANK-L expression in osteoblasts infected with S. aureus strain UAMS-1 (MOI ϭ 75:1) was 10-fold greater than RANK-L expression in uninfected cells at 4 h following infection (Fig. 1) . RANK-L mRNA expression by osteoblasts also increased in a dose-dependent manner. In addition, we showed that there was a time-dependent increase (Fig. 1) , with the expression of RANK-L mRNA by infected cells being 10-fold greater than the expression in the uninfected controls at 4 h. To confirm that the changes in RANK-L mRNA result in corresponding protein expression, cell-associated RANK-L was measured by specific-capture ELISA. As shown in Fig. 2 , there was a time-and dose-dependent response to S. aureus strain UAMS-1. At 24 h and at an MOI of 75:1, there was a 2.5-fold increase in the RANK-L protein compared to results with the control. Although the documented effects of RANK-L have been shown to be mediated by the membrane-bound form, we still measured the levels of soluble RANK-L as well and found its levels to be undetectable (data not shown). Osteoblasts infected with S. carnosus and UV-killed S. aureus strain UAMS-1 demonstrated the same levels of RANK-L protein expression as uninfected osteoblasts (Fig. 2) . Additionally, osteoblasts infected with S. aureus nasopharyngeal isolates N3 and N4 induced RANK-L production at levels similar to those for strain UAMS-1 at 0 h. Strains N4 and N3 sustained this increased RANK-L expression following 6 and 24 h of incubation, respectively.
Induction of PGE 2 expression by osteoblasts following exposure to S. aureus. Choi et al. demonstrated that PGE 2 is a main mediator in RANK-L-dependent osteoclastogenesis induced by several periodontal pathogens (8) . Therefore, it is possible that RANK-L production in osteoblasts infected with S. aureus involves a PGE 2-dependent mechanism. The current study examined levels of PGE 2 following infection of osteoblasts by S. aureus. Figure 3 demonstrates that PGE 2 is upregulated by S. aureus strain UAMS-1-infected osteoblasts at all time points examined. Although there is no significant difference between infection at an MOI of 25:1 and that at 75:1, there is a significant difference in PGE 2 expression between S. aureus strain UAMS-1-infected and uninfected osteoblasts. Figure 3 also shows that the increase in levels of PGE 2 occurs early following S. aureus infection and the levels remain elevated throughout the 24-h duration of the experiment. PGE 2 expression in response to UV-killed S. aureus strain UAMS-1-or S. carnosus-infected osteoblasts is not significantly different from that observed for uninfected osteoblasts (Fig. 3) . Although S. aureus nasopharyngeal isolates N1 to N5 significantly increase PGE 2 expression at time zero, PGE 2 levels following 6 and 24 h of infection are comparable to those for uninfected osteoblasts. PGE 2 production mediates S. aureus-induced increases in RANK-L production by osteoblasts. One of the steps in the PGE 2 synthesis pathway involves the conversion of arachidonic acid to PGH 2 , which is then metabolized to PGE 2 , by COX. The addition of NS-398, a selective inhibitor of COX-2, inhibits IL-1-induced PGE 2 synthesis (7, 48) . Therefore, in the current study, it is hypothesized that inhibition of COX-2 by NS-398 will result in decreased levels of PGE 2 production by S. aureus-infected osteoblasts. Figure 4 demonstrates that NS-398 significantly attenuates PGE 2 production in both uninfected and S. aureus-infected osteoblasts. Infected control cells treated with DMSO show the same dose response to S. aureus strain UAMS-1 seen in Fig. 3 .
Since it is known that PGE 2 upregulates RANK-L, we also examined the effects of NS-398 on RANK-L expression by S. aureus-infected osteoblasts. When infected osteoblasts are treated with NS-398, RANK-L levels are attenuated, indicating S. aureus-induced PGE 2 plays a role in expression of RANK-L by infected cells (Fig. 5) . 
DISCUSSION
Osteomyelitis is a disease associated with abnormal bone remodeling and massive bone resorption. The mechanisms responsible for such bone loss are largely unclear. The generation of proinflammatory cytokines and chemokines helps recruit immune cells, such as leukocytes, which could alter the balance between bone resorption and formation. Recent studies in our laboratory have demonstrated S. aureus-infected osteoblasts as a hitherto unrecognized source of soluble immune modulators both in vivo and in vitro (3-5, 14, 29, 30) . Osteoblasts can also produce other soluble factors that can modulate the activity or formation of osteoclasts. RANK-L is one such key molecule that stimulates differentiation in osteoclasts and is an inducing agent involved in bone destruction (24, 25, 46, 49, 57) . Following the binding of RANK-L to its receptor, RANK, on osteoclast precursors, the signal transduction can diverge into diverse pathways that can regulate distinct aspects of osteoclast functions (10, 18, 35, 39, 56) .
Bacterial pathogens can stimulate osteoclastogenesis, either directly or indirectly, which can potentiate bone resorption, leading to bone destruction (31, 36 (19) . Based on these findings, we undertook this study to evaluate the production of RANK-L from S. aureus-infected primary osteoblasts. Results outlined in Fig. 1 and 2 demonstrate that the viable S. aureus strain UAMS-1 is a potent inducer of membrane-bound, and not secreted, RANK-L mRNA and protein production by osteoblasts. In addition, UV-killed S. aureus strain UAMS-1 did not induce RANK-L expression, thus indicating that active bacterial gene expression may be required for maximal RANK-L production. Similarly, S. carnosus, an invasion-deficient species, did not stimulate increased RANK-L expression. Although osteoblasts infected with S. aureus nasopharyngeal isolates N3 and N4 induce RANK-L expression comparable to expression from osteoblasts infected with the osteomyelitis clinical isolate UAMS-1 at time zero and the strains maintain induction at 6 h in one case and at 24 h in the other, it is possible that strains N3 and N4 are capable of inducing osteomyelitis if they gain access to the bloodstream and subsequently to bone. The majority of the nasopharyngeal isolates are not capable of inducing RANK-L production. Taken together, these findings substantiate that live S. aureus is required for maximal RANK-L production from infected osteoblasts. An increase in RANK-L production by infected osteoblasts can further osteoclast differentiation and activation, which can potentiate the exacerbated bone destruction observed during osteomyelitis. While RANK-L potentiates osteoclastogenesis, Osteoprotegerin (OPG), produced and secreted by osteoblasts, is a negative regulator of osteoclast formation. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (43) is another key molecule produced by osteoblasts which can bind to OPG. Alexander et al. have demonstrated that when osteoblasts are infected with S. aureus, TRAIL expression is increased (2). Since OPG is known to bind both TRAIL and RANK-L, competition may limit the amount of OPG available to block the interaction between RANK-L and RANK during infection of osteoblasts by S. aureus. Taken together, it is highly likely that the increased levels of RANK-L contribute to the massive bone loss and aberrant bone remodeling associated with the pathology of staphylococcal osteomyelitis.
We next attempted to delineate the mechanism involved in upregulation of RANK-L expression in osteoblasts following exposure to S. aureus. PGE 2 is produced in bone mainly by osteoblasts and acts as a potent stimulator of bone resorption (37, 40, 46) . It has been demonstrated that PGE 2 can mediate RANK-L-dependent osteoclastogenesis in periodontal diseases (8) . Furthermore, the production of PGE 2 by osteoblasts is regulated by several cytokines and is also reported to induce osteoclast formation in mouse bone marrow cultures and stimulate bone resorption in mouse calvarial cultures (1, 7, 48) . We therefore hypothesized that increased RANK-L expression in infected osteoblasts occurs as a result of PGE 2 activation upstream in the RANK-L pathway. The current study demonstrates that live S. aureus strain UAMS-1 induces significant PGE 2 production in infected osteoblasts (Fig. 3) . However, UV-killed S. aureus strain UAMS-1 and S. carnosus do not induce PGE 2 production by osteoblasts. Osteoblasts infected with S. aureus nasopharyngeal isolates N1 to N5 demonstrate increased PGE 2 expression initially and decreased expression subsequently comparable to uninfected osteoblasts. Increased and sustained levels of PGE 2 production are induced only by live osteomyelitis clinical isolate UAMS-1, indicating the strain is capable of potentiating the bone damage observed in osteomyelitis. These results, along with the RANK-L data, are consistent with our previous findings that live S. aureus strain UAMS-1 is more effective at eliciting immune modulator production by cultured osteoblasts than UV-killed bacteria or nonpathogenic species (3) (4) (5) 11) .
The functions of PGE 2 in target cells are mediated by four different G-protein-coupled receptor subtypes, EP1, EP2, EP3, and EP4 (28, 47) . Among these PGE 2 receptor subtypes, EP4 is the main receptor expressed on osteoblasts and is responsible for mediating PGE 2 -induced RANK-L expression by osteoblasts (13, 47, 52) . In addition, PGE 2 synergistically promotes the differentiation of bone marrow macrophages into osteoclasts induced by RANK-L and macrophage colony-stimulating factor (51, 55) . Thus, PGE 2 stimulates osteoclastic bone resorption through the following two different pathways: the induction of RANK-L expression in osteoblasts and the direct enhancement of RANK-L-induced differentiation of osteoclast precursor cells into osteoclasts. The mechanism of the synergistic effect of PGE 2 on the RANK-L-induced osteoclastic differentiation of precursor cells has not yet been explained (23) . PGE 2 synthesis is regulated by three metabolic steps: the release of arachidonic acid from the membranous phospholipids by phospholipase A 2 , the conversion of arachidonic acid to PGH 2 by COX, and the synthesis of PGE 2 by PGE synthase (26, 34, 44) . Both constitutive COX (COX-1) and inducible COX (COX-2) are expressed in mouse osteoblasts, with COX-2 being markedly induced by several bone-resorbing, inflammatory factors, including IL-1 and IL-6, in osteoblasts (32, 47) . To establish the role of COX-2 with respect to production of PGE 2 during infection of osteoblasts with S. aureus, we used NS-398 to inhibit COX-2 and examined its effect on PGE 2 expression. When osteoblasts were treated with NS-398, PGE 2 levels were significantly attenuated in both uninfected and S. aureus-infected osteoblasts (Fig. 4) . These results indicate that COX-2 is important in the regulation of PGE 2 production during S. aureus infection of osteoblasts.
We next examined the effects of NS-398 on the production of RANK-L. Although NS-398 significantly reduced the amount of RANK-L produced by S. aureus-infected osteoblasts, levels of RANK-L still remained detectable and were still responsive to S. aureus infection (Fig. 5) . These data suggest that COX-2 and PGE 2 play a significant role in potentiating RANK-L production by S. aureus-infected osteoblasts.
The increasing incidence of bacterial infections caused by S. aureus and the emergence of antibiotic-resistant strains of this organism have made it imperative that we understand the mechanisms of initiation and maintenance of inflammation, as well as those of bone loss observed in sites of infection, in order to develop safe and effective therapies. Data presented here clearly outline a mechanism by which RANK-L, an essential factor for osteoclastogenesis, is upregulated by S. aureus strain UAMS-1-infected osteoblasts, further substantiating the role that osteoblasts may have in the aberrant bone remodeling observed in staphylococcal osteomyelitis. In addition, this upregulation of RANK-L appears to involve a COX-2-mediated PGE 2 -dependent pathway. Potentially, agents that inhibit COX-2 or block RANK-L production could ameliorate bone loss. Further studies are warranted to investigate the in vivo significance of RANK-L in S. aureus-induced osteomyelitis.
